1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Moderna Peers Into Post-Pandemic Future For Respiratory Vaccines

 
• By Alaric DeArment

The company had its fourth vaccines day, where it talked about its strategy over the next few years for vaccines against COVID-19, RSV, flu and combinations thereof.

Moderna had its fourth vaccine R&D day on 11 April • Source: Shutterstock

Moderna, Inc. has laid out clear plans for how it intends to become a significant player in the market for vaccines against respiratory diseases – COVID-19, respiratory syncytial virus (RSV) and influenza – over the next several years, first with vaccines against each individual disease and subsequently with combination products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 
• By Anju Ghangurde

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

 
• By Alaric DeArment

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.

Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs

 
• By Alaric DeArment

The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.